Roxadustat, an hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, which mimics the body's response to hypoxia, has been shown to lower hepcidin levels in CKD-related anemia (52). This evidence concerns the gene HAMP and chronic kidney disease.